Advanced Cell Therapy for Childhood Cancers

A study led by Dr. Alexandra Avgustinova and Dr. Holger Heyn (CNAG), published in Annals of Oncology, has identified immune cells with strong anti-tumour activity in aggressive paediatric rhabdoid tumour. The findings stem from an in-depth analysis of a single patient followed over time using advanced sequencing technologies, which allowed the researchers to track how immunotherapy activated specific T cell populations capable of recognizing and controlling the tumour.

The work has shown that these tumour-reactive cells and their receptors can be characterized and potentially engineered, laying the foundation for personalized cell therapies such as TCR-T approaches. These findings provide a mechanistic basis for the patient’s sustained remission and open new directions for designing tailored immunotherapies for children with rare and highly aggressive cancers.

More information: An aggressive childhood cancer case opens new avenues for advanced cell therapies